Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review

Circulation

Volumn 104, Issue 25, 2001, Pages 3063-3068

  Boekholdt, S Matthijs ^a   Bijsterveld, Nick R ^a   Moons, Arno H M ^a   Levi, Marcel ^a   Büller, Harry R ^a   Peters, Ron J G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Coagulation; Genetics; Myocardial infarction

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FIBRINOLYSIS; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0035909969     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc5001.100793     Document Type: Article

References (52)

1. The role of plaque rupture and thrombosis in coronary artery disease
2. Clinical epidemiological quality in molecular genetic research
3. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease?
4. Introduction to stratified analysis
5. Polymorphisms in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease
6. Incidence of factor V Leiden in patients with acute myocardial infarction
7. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension
8. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study
9. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
10. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
11. Factor V (Arg506Gln) mutation in young survivors of myocardial infarction
12. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
13. Prothrombotic genetic risk factors in young survivors of myocardial infarction
14. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males
15. Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men
16. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography
17. Evidence against heterozygous coagulation factor V 1691 G/A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction
18. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease
19. Coagulation factors II, V, VII, and X, prothrombin gene 20210 G/A transition, and factor V Leiden in coronary artery disease: High factor V clotting activity is an independent risk factor for myocardial infarction
20. Factor V Arg506Gln mutation is not associated with cardiovascular mortality in older women
21. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction
22. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries
23. The prothrombin 20210A allele and its association with myocardial infarction
24. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men
25. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
26. Prevalence of the prothrombin 20210 G-to-A variant in blacks, infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects
27. The 20210 G/A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease
28. Prevalence of the prothrombin gene variant 20210 G/A among patients with myocardial infarction
29. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease
30. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease
31. A variant of beta fibrinogen is a genetic risk factor for coronary artery disease and myocardial infarction
32. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction: The ECTIM Study
33. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
34. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden
35. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly
36. Association of a common polymorphism in the factor XIII gene with myocardial infarction
37. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
38. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
39. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
40. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
41. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease
42. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
43. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction
44. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
45. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism
46. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes
47. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population
48. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women
49. Plasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population
50. Genetic polymorphisms and coronary artery disease in the south of France
51. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
52. A common mutation (G-455A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease